Kornimate/medical-research-clean huggingface dataset:
assesment of physical activity level of patients with multiple sclerosis: from laboratory to real life

Conditions: Multiple Sclerosis

Summary: this study aims to assess the feasibility of a protocol determining individual moderate-to-vigorous physical activity (mvpa) thresholds, among multiple sclerosis patients, in routine medical practice.


Eligibility criteria:
inclusion criteria: * patients aged 18 to 80 years old * multiple sclerosis according to mcdonald criteria ; * expanded disability status scale (edss) between 0 and 6.5 ; * patient able to move with or without mechanical assistance. exclusion criteria: * deterioration of neurological symptomatology within 60 day before enrollment ; * changes brought to the multiple sclerosis treatment within 6 months before enrollment ; * introduction of a treatment acting on spasticity or fatigue within 30 day before enrollment * changes brought to reeducation protocol throughout the duration of the study * patient unable to provide an effort equivalent to 3 times the resting metabolic value = 3 metabolic equivalent of task (mets).
feasibility of vmat and cbct for head and neck carcinomas

Conditions: Head and Neck Carcinoma

Summary: this will be a prospective longitudinal study describing clinical throughput metrics and patient reported quality of life outcome measures for patients undergoing volumetric modulated arc therapy (vmat) with and without cone-beam computed tomography (cbct) for head and neck carcinoma at the british columbia cancer agency. 1. vmat for the treatment of patients with hnc will provide opportunities for image-guided radiotherapy using cbct online correction to reduce systematic and random error. 2. analysis of patient reported quality of life outcomes during vmat, with and without cbct acquisition, will be hypothesis generating.


Eligibility criteria:
inclusion criteria: * age greater than 18 years * undergoing radical radiation therapy for head and neck carcinoma at the bc cancer agency exclusion criteria: * treatment being offered is not for curative intent * patient has received previous radiation for head and neck cancer * patient has systemic lupus erythematosis or scleroderma * patients has other autoimmune connective tissue disorders
transcutaneous auricular vagus nerve stimulation for meniere disease

Conditions: Meniere Disease

Summary: objective: to evaluate the effect of transcutaneous auricular vagus nerve stimulation for the patients meniere disease. methods: we enrolled 231 patients at beijing tongren hospital. all treatments were self-administered by the patients at home after training at the hospital. patients completed questionnaires at baseline, 3 months, 6 months, and 12 months. video head impulse test (vhit), the caloric test, tinnitus handicap inventory (thi), dizziness handicap inventory (dhi), pure tone audiometry, and visual scale of ear stuffiness to evaluate the therapeutic effects. a difference of p \< 0.05 was considered statistically significant.


Eligibility criteria:
inclusion criteria: * 1. age \>=18 and age \<=65. 2. clinical diagnosis of meniere disease. exclusion criteria: 1. history of depression, tumors, thyroid disease, diabetes, cardiac diseases. 2. history of otorhinolaryngology surgery. 3. pregnant or lactating women.

Keywords: meniere disease, tavns, case-control, retrospective
violence brief intervention pilot v1.1

Conditions: Alcohol Consumption; Violence; Facial Injuries

Summary: this study is a randomised controlled trial of a new brief intervention with young (16-29) adult male patients who have a facial injury sustained as a result of interpersonal violence (fighting or assaults). it will be undertaken at the maxillofacial outpatient trauma clinic at the southern general hospital, glasgow. the major risk factors associated with facial injury in scotland are male gender, young age, interpersonal violence and alcohol. previous research with facial injury patients attending this clinic has shown that an alcohol brief intervention (abi) is effective in helping reduce alcohol consumption, so all patients are now offered abi as standard practice. abi is delivered by trained nurses from addiction services. this will not be withdrawn. in addition we wish to offer some patients a violence brief intervention (vbi). this will be delivered by the same nurses who deliver the abi. the study is randomised so only those selected at random will receive this extra intervention and all others will receive treatment as normal (abi only). vbi is a short psychological intervention which uses brief motivational interviewing (bmi) to encourage reflection of involvement in violence and consideration of strategies to avoid future violence. the intervention also compares participants' attitudes towards violence to those of their peers. the intervention takes about 15 minutes, and patients will be involved for an additional 30-45 minutes longer than normal when they attend the clinic, including consent and baseline data collection. patients will be followed up by telephone at 1, 3 and 6 months, and asked a suite of questions which will take approximately 15 minutes on each occasion. we wish to determine whether a vbi of this type has any effect on attitudes to violence or propensity for involvement in violence or on reinjury, examined through self report measures and routinely collected health and criminal justice data at 12 months post intervention.


Eligibility criteria:
inclusion criteria: * facial trauma patients * facial injury resulting from interpersonal violence (whether victim or perpetrator) * able to give informed consent * willing to commit to screening intervention and follow up programme lasting 6 months * within 28 days of injury * willing to provide either a contact telephone number or email address for the followup surveys * participants score ≥ 3/16 on the fast alcohol screening test (fast) exclusion criteria: * unable to give informed e.g. adults with dementia, severe psychiatric problems, patients with learning difficulties who cannot consent for themselves * under 16 or over 29 years of age. * injury more than 28 days old * participants score ≤ 2/16 on the fast measure
phase iii randomized controlled study of morphine and nortriptyline in the management of postherpetic neuralgia

Conditions: Pain; Herpes Zoster

Summary: objectives: i. determine whether opioid (morphine) treatment results in better management of pain than treatment with tricyclic antidepressant (nortriptyline). ii. assess the effects the two treatments have on affective and cognitive functions. iii. determine whether the presence of psychiatric comorbidity, particularly depression, can predict the outcome of the two treatments.

protocol outline: this is a randomized, double blind, crossover study. patients are stratified by the duration of pain (greater than 1 year or no greater than 1 year) and the presence or absence of major depression. patients are randomized into 6 treatment order groups. patients start with nortriptyline, morphine, or placebo, taken orally every day. if patients are unable to tolerate nortriptyline or morphine, they will receive desipramine or methadone instead. a drug titration period lasting 3 weeks is ensued for administration of the first drug treatment. the goal of this titration period is to gradually increase the dose of the drug to obtain maximal analgesic efficacy. drug dosage is maintained for a period of 3 weeks. the drug dosage is tapered off and followed by a drug free period of 1 week.

Eligibility criteria:
protocol entry criteria: --disease characteristics-- * diagnostically confirmed postherpetic neuralgia for at least 3 months following a segmental herpes zoster eruption --prior/concurrent therapy-- * other: no concurrent monoamine oxidase inhibitors --patient characteristics-- * life expectancy: at least 6 months * cardiovascular: no second degree or complete heart blockage no myocardial infarction in the last 3 months * pulmonary: no severe pulmonary disease * other: no history of substance abuse no history of dementia no history of encephalopathy no severe depression that precludes withdrawal from antidepressants not pregnant no angle-closure glaucoma no aids related disease complex no terminal disease with life expectancy of less that 6 months

Keywords: disease-related problem/condition herpes zoster infection herpesvirus infection immunologic disorders and infectious disorders pain rare disease viral infection
study to describe the management and the use of healthcare resources in patients with chronic lymphocytic leukemia (cll) initiating venetoclax in routine clinical practice

Conditions: Chronic Lymphocytic Leukemia

Summary: a study to assess the real-life management and use of healthcare resources during the initiation of: * venetoclax in combination with rituximab is indicated for the treatment of adult participants with chronic lymphocytic leukemia (cll) who have received at least one prior therapy. * venetoclax in participants with cll with the deletion of the short arm of chromosome 17 (del\[17p\]) who have received at least 1 prior therapy or participants with cll without del(17p) who have received at least 1 prior therapy and for whom there are no other available treatment options.


Eligibility criteria:
inclusion criteria: * patient's physician prescribed venetoclax as per product monograph independent of the patient participation in this study. * has chronic lymphocytic leukemia (cll) and has received at least one prior therapy. exclusion criteria: * currently participating in an interventional study. * has other condition that, in the opinion of the treating physician, prohibits the patient from participating in the study or obscures the assessment of the treatment of cll.

Keywords: chronic lymphocytic leukemia (cll) deletion of the short arm of chromosome 17 (del[17p]) relapse chronic lymphocytic leukemia refractory chronic lymphocytic leukemia chronic lymphocytic leukemia with deletion of the short arm of chromosome 17 cancer
dermacyd ph_detinlyn (lactic acid) sweet flower - photo evaluation.

Conditions: Hygiene

Summary: to demonstrate the absence of photoirritation and photosensitization potential of the product dermacyd phdetinlyn sweet flower.


Eligibility criteria:
inclusion criteria: * phototype skin ii and iii; * integral skin test in the region; * willingness in following the study procedures and to be present in the clinic at the days and scheduled time for medical evaluations and for application of occlusion; exclusion criteria: * lactation or gestation * use of antiinflammatory and/or immunosuppression drugs 15 days before the selection; * diseases which can cause immunity decrease, such as hiv, diabetes; * use of drug photosensitizer; * history of sensitivity or irritation for topic products; * active cutaneous disease which can change the study results; * history of photodermatosis active; * family or personal antecedent of cutaneous photoinduced neoplasias; * presence of a precursor lesion of cutaneous neoplasia, such as nevus melanocyte and queratoses actinium; * intense solar exposure in the study area; * use of new drugs or cosmetics during the study the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
scale: small changes and lasting effects

Conditions: Overweight; Obesity

Summary: the goal of this study is to translate basic behavioral and social science discoveries into effective behavioral interventions that reduce obesity and obesity related morbidity in black and latino communities. this intervention will focus on promoting small changes in eating behavior and increasing physical activity among black and latino participants in harlem and the south bronx. the desired result from these activities is individual weight loss that will be sustained years after participation in the study.

scale is a five year study (october 1, 2009 through june 30, 2014) funded by nhlbi. the study will examine the possibility and acceptance of a mindful eating intervention in african american and latino participants. we will test whether positive thinking can protect participants against the negative impact that stress and depression can have on making positive behavior changes such as mindful eating and physical activity. currently, the scale study is in the trial phase. among overweight or obese black or latino adults who live in harlem or the south bronx, the primary goal of this project is to achieve weight loss of 7% or more over 12 months by making small sustained changes in eating behavior coupled with sustained increases in physical activity. participants are enrolled for 12 months and are randomized to one of two study groups. group 1: will choose one of ten small change eating strategies, a physical activity goal and will receive the positive affect/self affirmation component. group 2: will choose one of ten small change eating strategies and a physical activity goal for inquiries regarding potential enrollment in this study, please contact rosio ramos at 646-962-5070 or email ror2023@med.cornell.edu

Eligibility criteria:
inclusion criteria: eligibility criteria: black or latino community-dwelling subjects who are 21 years or older and have a body mass index of \>25 but \<50 or considered to be obese or overweight are be eligible for study participation. all participants must be able to participate in physical activity and must be fluent in english or spanish. exclusion criteria: subjects will be excluded if: 1. unable to provide informed consent in either english or spanish for any reason, including cognitive impairment, psychiatric illness, drug or alcohol addiction 2. pregnant or are planning to become pregnant within the year 3. participating in another weight loss program or trial 4. on medications for obesity 5. have a history of bulimia; 6. history of surgery for obesity; 7. have severe comorbid diseases that can lead to unintentional weight change including cancer, hiv/aids, congestive heart failure. 8. they live in an institutional setting (nursing home, prison or group home). 9. have severe disease or are terminally ill, including stroke, myocardial infarction, coronary artery disease requiring angioplasty. -
impact of c-arm ct in decreased renal function undergoing tace for tx of hepato-cellular carcinoma

Conditions: Kidney (Renal Cell) Cancer

Summary: impact on contrast dose or total volume of contrast required to effectively treat the targeted tumor.


Eligibility criteria:
inclusion criteria: 1. patients must be affected by hcc 2. patients must have diminished renal function (gfr\<60 ml/min/1.73m\^2) 3. patients must be 18 years old or older 4. patients must have received an abdominal ct, pet/ct scan or mri, completed prior to the tace procedure. 5. ability to understand and the willingness to sign a written informed consent document. exclusion criteria: 1. subjects under the age of 18 2. patients currently on dialysis 3. pregnant women
the role of platelet tlrs in platelet activation during vte

Conditions: Venous Thromboembolism

Summary: venous thromboembolic disease (vte) is a frequent and potentially serious pathology. therapeutic management has improved considerably over the last few decades, enabling the application of codified management in line with the recently updated french management recommendations. one of the main remaining difficulties concerns vte sequelae, mainly post-thrombotic syndrome after deep vein thrombosis, and post-pulmonary embolism syndrome after pulmonary embolism. the mechanisms leading to the absence of complete repermeabilization of vessels affected by venous thromboembolic disease (vte) are still poorly understood. the concept of immunothrombosis, closely associating immunity, inflammation and thrombosis, could (in part) explain the appearance of these sequelae. platelets appear to play a key role in the onset of sequelae: platelets are known to be involved both in the onset of a vte episode and in the inflammatory response. this involvement is illustrated by the expression of inflammatory receptors such as tlr (toll-like receptor) 2 and tlr4. th aim to investigate the role of platelets in the occurrence of sequelae, mainly via their role in the inflammatory response, in venous thromboembolic disease (vte) patients.


Eligibility criteria:
inclusion criteria: * patients diagnosed with venous thromboembolic (vte) / proximal deep vein thrombosis (dvt) of the lower limb and/or pulmonary embolism ≤ 72heures * patients are 18 years of age or older at diagnosis. * patients received informed written consent * patients benefiting from social security coverage exclusion criteria: * diagnosis of venous thromboembolic (vte) more than 72 hours old * isolated sub-segmental pulmonary embolism * patients on antiplatelet agents * patients on non-steroidal anti-inflammatory drugs (nsaids) * life expectancy \> 3 months

Keywords: venous thromboembolism vte sequelae immunothrombosis platelets inflammatory receptors
optimizing diagnostics of syncope events using intelligent telemetric solutions.

Conditions: Cardiac Arrhythmia; Cardiogenic Syncope

Summary: the purpose of this study is to assess efficacy of prolonged full disclosure electrocardiogram (ecg) monitoring and signal analysis using advanced telemetric technology to diagnose syncope in comparison with standard diagnostic procedure

syncope can be caused by many conditions, often benign but in some cases syncope can be a symptom of severe arrhythmia. early diagnosis of the underlying disease is very important to identify patients with severe cardiac arrhythmia to commence adequate treatment. standard diagnostic methods such as 24 hours holter electrocardiogram (ecg) monitoring or event holter do not guarantee early diagnosis of the arrhythmia. prolonged heart rhythm recording and analysis using an automatic full disclosure telemetric device can increase probability of arrhythmia diagnosis and early administration of adequate treatment. study patients will be diagnosed using standard holter ecg monitoring, event holter or 30 days telemetric ecg monitoring. efficacy of telemetric monitoring in diagnosis of cardiac arrhythmia will be assessed in comparison with the standard holter monitoring and event holter.

Eligibility criteria:
inclusion criteria: * history of syncope * ability to operate the telemetric device at home * exclusion of underlying neurological disease * informed consent undersigned by the parents * informed consent undersigned by the child if over 16 years of age exclusion criteria: * syncope with known underlying disease * inability to operate the telemetric device at home * complete heart block * qt\>500ms * implantation of icd * inability to comply with the study protocol

Keywords: cardiac arrhythmia cardiogenic syncope pediatrics children
exercise for elderly peripheral revascularized patients

Conditions: Peripheral Artery Disease; Intermittent Claudication

Summary: the purpose of this study is (1) to determine whether a 3-month exercise rehabilitation program will improve claudication distances, free-living daily physical activity, and health-related quality of life of older, revascularized patients with peripheral arterial disease, and (2) to determine whether the primary mechanisms by which exercise rehabilitation affects the above functional outcomes are through alterations in walking efficiency, peripheral circulation, and cardiopulmonary function.

peripheral arterial disease (pad) patients with critical limb-threatening ischemia have improved peripheral circulation following infrainguinal revascularization. despite this hemodynamic benefit, little change in functional status occurs, and many patients have residual ambulatory dysfunction. the lack of functional improvement in revascularized patients may be due to extreme physical deconditioning secondary to their pre-existing critical limb-threatening ischemia. therefore, we hypothesize that a program of aerobic exercise training is necessary to optimize ambulation, free-living daily physical activity, and health-related quality of life through the mechanisms of improved walking economy, peripheral circulation, and cardiopulmonary function. this is a prospective, randomized controlled clinical trial comparing an exercise group undergoing a program of graded treadmill walking, and a non-exercise control group. eighty pad patients will be randomized into either the exercise group (n = 40) or the non-exercise control group (n = 40) following successful lower extremity arterial bypass or angioplasty. the 3-month exercise program will consist of graded treadmill walking 3 times per week with progressive increments in exercise duration from 15 to 40 minutes, and progressive increments in exercise intensity from 50 to 80% of exercise capacity.

Eligibility criteria:
inclusion criteria: * lower extremity arterial bypass at least 3 months prior to screening * infrainguinal percutaneous transluminal angioplasty (ptla) at least 2 weeks prior to screening exclusion criteria: * persistent rest pain due to (peripheral artery disease (pad) (fontaine stage iii for pad), * persistent tissue loss due to paod (fontaine stage iv for pad), * medical conditions that are contraindicative for exercise according to the american college of sports medicine (e.g., acute myocardial infarction, unstable angina, etc.) * cognitive dysfunction (mini-mental state examination score of less than 24)

Keywords: functional ability gait musculoskeletal disorder therapy peripheral blood vessel disorder
evaluation of anterior middle brain structures with cerebrovascular flow in fetuses with fetal growth restriction

Conditions: Fetal Growth Retardation; Fetal Neurodevelopmental Disorder

Summary: the study will be conducted to examine the effects of abnormal growth pattern and cerebrovascular blood flow measurements on fetal frontal lobe development with the advancing ultrasound technology. antenatal assessment of frontal lobe development will enable clinicians to predict neurodevelopmental problems that may develop postnatally. in addition, this study will examine the effects of fgr on frontal lobe development.

fetal growth restriction (fgr) affects up to 10% of all pregnancies. the international society of ultrasound in obstetrics \& gynecology (isuog) adopts the delphi consensus criteria for the definition of fgr. these criteria include estimated fetal weight (efw) or abdominal circumference (ac) \< 3rd percentile or efw or ac \< 10th percentile with abnormal doppler findings or decreased growth percentiles. fgr is a cause of perinatal morbidity and mortality. these perinatal outcomes include cardiovascular, endocrine and neurodevelopmental disorders. fetal growth restriction, which is associated with lower neurobehavioral test scores, is associated with significant postnatal costs for both the health care system and families. previous literature has shown that three-dimensional ultrasonography of intracranial structures reveals significant differences between fetuses with fgr and gestational age-appropriate (aga) fetuses. however, the limited use of three-dimensional ultrasonography has hindered clinical applications. the frontal anterior-posterior diameter (fapd)/occipital-frontal diameter (ofd) ratio has recently been used to assess frontal lobe development in fetuses with congenital heart disease. the fapd is obtained by measuring from the inner line of the frontal bone along the fetal brain midline to the posterior edge of the csp. this measurement refers to the frontal lobe of the fetal cerebrum. this study was designed to investigate the fapd/ ofd ratio and frontal lobe development in fetuses with fgr and to evaluate cerebrovascular flow and anterior midbrain structures in fgr fetuses.

Eligibility criteria:
inclusion criteria: * healthy hearts between the ages of 18-40 * singleton pregnancies * 32 to 37 weeks gestational week range exclusion criteria: * multiple pregnancies * fetuses with fetal karyotype abnormalities * pregnant women with co-morbidity * fetuses with fetal intracranial hemorrhage * fetuses with cranial anomalies * maternal obesity preventing measurement

Keywords: fetal growth restriction anterior middle brain structures cerebrovascular flow